Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders - PubMed

Affiliations

• PMID: 21874377
• DOI: 10.1007/s11095-011-0546-y

Review

Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders

Lefkothea C Papadopoulou et al. Pharm Res. 2011 Nov.

Abstract

Protein therapy is considered an alternative approach to gene therapy for treatment of genetic-metabolic disorders. Human protein therapeutics (PTs), developed via recombinant DNA technology and used for the treatment of these illnesses, act upon membrane-bound receptors to achieve their pharmacological response. On the contrary, proteins that normally act inside the cells cannot be developed as PTs in the conventional way, since they are not able to "cross" the plasma membrane. Furthermore, in mitochondrial disorders, attributed either to depleted or malfunctioned mitochondrial proteins, PTs should also have to reach the subcellular mitochondria to exert their therapeutic potential. Nowadays, there is no effective therapy for mitochondrial disorders. The development of PTs, however, via the Protein Transduction Domain (PTD) technology offered new opportunities for the deliberate delivery of human recombinant proteins inside eukaryotic subcellular organelles. To this end, mitochondrial disorders could be clinically encountered with the delivery of human mitochondrial proteins (engineered via recombinant DNA and PTD technologies) at specific intramitochondrial sites to exert their function. Overall, PTD-mediated Protein Replacement Therapy emerges as a suitable model system for the therapeutic approach for mitochondrial disorders.

Similar articles

• Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient's primary cells.

  Foltopoulou PF, Tsiftsoglou AS, Bonovolias ID, Ingendoh AT, Papadopoulou LC. Foltopoulou PF, et al. Biochim Biophys Acta. 2010 Jun;1802(6):497-508. doi: 10.1016/j.bbadis.2010.02.009. Epub 2010 Mar 1. Biochim Biophys Acta. 2010. PMID: 20193760

• [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].

  Furukawa R, Yamada Y, Harashima H. Furukawa R, et al. Yakugaku Zasshi. 2012;132(12):1389-98. doi: 10.1248/yakushi.12-00235-3. Yakugaku Zasshi. 2012. PMID: 23208046 Review. Japanese.

• Mitochondrial Protein Network: From Biogenesis to Bioenergetics in Health and Disease.

  Ferramosca A. Ferramosca A. Int J Mol Sci. 2020 Dec 22;22(1):1. doi: 10.3390/ijms22010001. Int J Mol Sci. 2020. PMID: 33374898 Free PMC article.

• Approaches and limitations to gene therapy for mitochondrial diseases.

  Owen R 4th, Flotte TR. Owen R 4th, et al. Antioxid Redox Signal. 2001 Jun;3(3):451-60. doi: 10.1089/15230860152409086. Antioxid Redox Signal. 2001. PMID: 11491656 Review.

• Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.

  Yamada Y, Harashima H. Yamada Y, et al. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1439-62. doi: 10.1016/j.addr.2008.04.016. Epub 2008 Jul 4. Adv Drug Deliv Rev. 2008. PMID: 18655816 Review.

Cited by

• Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

  Slastnikova TA, Rosenkranz AA, Zalutsky MR, Sobolev AS. Slastnikova TA, et al. Curr Pharm Des. 2015;21(9):1227-38. doi: 10.2174/1381612820666141013121032. Curr Pharm Des. 2015. PMID: 25312738 Free PMC article. Review.

• The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.

  Papadopoulou LC, Tsiftsoglou AS. Papadopoulou LC, et al. Pharmaceuticals (Basel). 2013 Jan 7;6(1):32-53. doi: 10.3390/ph6010032. Pharmaceuticals (Basel). 2013. PMID: 24275786 Free PMC article.

• PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients' RBCs ex vivo in the frame of Protein Replacement Therapy.

  Miliotou AN, Papagiannopoulou D, Vlachaki E, Samiotaki M, Laspa D, Theodoridou S, Tsiftsoglou AS, Papadopoulou LC. Miliotou AN, et al. J Biol Res (Thessalon). 2021 Jul 20;28(1):16. doi: 10.1186/s40709-021-00148-3. J Biol Res (Thessalon). 2021. PMID: 34284828 Free PMC article.

• Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency.

  Miliotou AN, Foltopoulou PF, Ingendoh-Tsakmakidis A, Tsiftsoglou AS, Vizirianakis IS, Pappas IS, Papadopoulou LC. Miliotou AN, et al. Pharmaceutics. 2023 Jan 14;15(1):286. doi: 10.3390/pharmaceutics15010286. Pharmaceutics. 2023. PMID: 36678915 Free PMC article. Review.

• In vivo biodistribution study of TAT-L-Sco2 fusion protein, developed as protein therapeutic for mitochondrial disorders attributed to SCO2 mutations.

  Kaiafas GC, Papagiannopoulou D, Miliotou ΑN, Tsingotjidou AS, Chalkidou PC, Tsika AC, Spyroulias GA, Tsiftsoglou AS, Papadopoulou LC. Kaiafas GC, et al. Mol Genet Metab Rep. 2020 Dec 8;25:100683. doi: 10.1016/j.ymgmr.2020.100683. eCollection 2020 Dec. Mol Genet Metab Rep. 2020. PMID: 33318931 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information